NCT05245721

Brief Summary

Effect of caudal nalbuphine on postoperative emergence agitation in pediatrics undergoing infra-umbilical surgeries and pain assessment

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P75+ for phase_1

Timeline
Completed

Started Mar 2022

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 18, 2022

Completed
1 month until next milestone

First Posted

Study publicly available on registry

February 18, 2022

Completed
11 days until next milestone

Study Start

First participant enrolled

March 1, 2022

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2023

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2023

Completed
Last Updated

February 18, 2022

Status Verified

February 1, 2022

Enrollment Period

10 months

First QC Date

January 18, 2022

Last Update Submit

February 8, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Effect of caudal nalbuphine on postoperative emergence agitation according to Pediatric Anasthesia emergence delirium (PAED)

    PAED ( The pediatric anesthesia emergence delirium scale)

    Up to 2 hours postoperative

Secondary Outcomes (1)

  • Postoperative pain assessment according to Modified Children's Hospital of Eastern Ontario Pain Scale (modified CHEOPS)

    For 24 hours postoperative

Study Arms (2)

Nalbuphine

ACTIVE COMPARATOR
Drug: NalbuphineDrug: Bupivacain

Bupivacaine

ACTIVE COMPARATOR
Drug: Bupivacain

Interventions

Caudal nalbuphine injection in pediatrics undergoing infra-umbilical surgeries

Nalbuphine

Caudal bupivacaine in pediatrics undergoing infra-umbilical surgeries

BupivacaineNalbuphine

Eligibility Criteria

Age2 Years - 12 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Age 2\_12 years
  • Both genders
  • ASA I\_II
  • Children undergoing infra-umbilical surgeries

You may not qualify if:

  • Guardians refusal
  • congenital anomalies at the lower spine or meringues
  • Increased intracranial pressure
  • Skin infection at site of injection
  • Bleeding diathesis
  • Known allergy to any drugs used

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Emergence DeliriumPain, Postoperative

Interventions

NalbuphineBupivacaine

Condition Hierarchy (Ancestors)

DeliriumConfusionNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesPostoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsSigns and SymptomsNeurocognitive DisordersMental DisordersPain

Intervention Hierarchy (Ancestors)

MorphinansOpiate AlkaloidsAlkaloidsHeterocyclic CompoundsHeterocyclic Compounds, Bridged-RingHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Fused-RingPhenanthrenesPolycyclic Aromatic HydrocarbonsPolycyclic CompoundsAnilidesAmidesOrganic ChemicalsAniline CompoundsAmines

Central Study Contacts

Rehab Adel Ebrahim

CONTACT

Mohamed Fathy Mostafa, Assistant professor

CONTACT

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
CARE PROVIDER
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant lecturer

Study Record Dates

First Submitted

January 18, 2022

First Posted

February 18, 2022

Study Start

March 1, 2022

Primary Completion

January 1, 2023

Study Completion

February 1, 2023

Last Updated

February 18, 2022

Record last verified: 2022-02